AN2 Therapeutics Ownership | Who Owns AN2 Therapeutics?

Overview Forecast RevenueFinancials Chart

AN2 Therapeutics Ownership Summary

AN2 Therapeutics is owned by 45.28% institutional investors, 21.64% insiders, and 33.08% retail investors. Ra capital management is the largest institutional shareholder, holding 18.65% of ANTX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.51% of its assets in AN2 Therapeutics shares.

ANTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	AN2 Therapeutics	45.28%	21.64%	33.08%
Sector	Healthcare Stocks	88.01%	8.90%	3.09%
Industry	Biotech Stocks	109.70%	8.77%	-18.47%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ra capital management	5.55M	18.65%	$11.94M
Tcg crossover management	1.56M	5.22%	$3.34M
Citadel advisors	1.55M	5.22%	$3.34M
Vanguard group	1.04M	3.50%	$2.24M
Millennium management	526.35K	1.77%	$1.13M
Adage capital partners gp	312.62K	1.05%	$672.12K
Blackrock	299.70K	1.01%	$644.36K
Goldman sachs group	224.19K	0.75%	$482.00K
Geode capital management	180.92K	0.61%	$389.10K
Two sigma advisers, lp	134.70K	0.45%	$289.61K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Tcg crossover management	1.56M	0.35%	$3.34M
Ra capital management	5.55M	0.16%	$11.94M
Marquette asset management	83.21K	0.02%	$114.83K
Bridgeway capital management	104.29K	0.01%	$224.23K
Adage capital partners gp	312.62K	0.00%	$672.12K
Citadel advisors	1.55M	0.00%	$3.34M
Acadian asset management	86.95K	0.00%	$185.00K
Two sigma advisers, lp	134.70K	0.00%	$289.61K
Two sigma investments, lp	132.09K	0.00%	$283.99K
Millennium management	526.35K	0.00%	$1.13M

Top Buyers

Holder	Shares	% Assets	Change
Millennium management	526.35K	0.00%	429.44K
Goldman sachs group	224.19K	0.00%	195.81K
Two sigma advisers, lp	134.70K	0.00%	134.70K
Bridgeway capital management	104.29K	0.01%	78.00K
Two sigma investments, lp	132.09K	0.00%	37.92K

Top Sellers

Holder	Shares	% Assets	Change
Octagon capital advisors lp	-	-	-3.22M
Frazier life sciences management	-	-	-2.09M
Bvf inc/il	-	-	-1.24M
Janus henderson group	-	-	-1.22M
Avidity partners management lp	-	-	-1.15M

New Positions

Holder	Shares	% Assets	Change	Value
Two sigma advisers, lp	134.70K	0.00%	134.70K	$289.61K
Schonfeld strategic advisors	21.77K	0.00%	21.77K	$46.81K
Renaissance	14.30K	0.00%	14.30K	$30.75K
Royal bank of canada	2.81K	-	2.81K	$6.00K
Jpmorgan chase	1.02K	-	1.02K	$2.19K

Sold Out

Holder	Change
Wells fargo & company/mn	-128.00
California state teachers retirement system	-9.25K
Clear street markets	-10.00K
Qube research	-10.19K
Atom investors lp	-11.90K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	31	-31.11%	13,513,224	-30.40%	45	1.06%	16	-20.00%	7	-46.15%
Jun 30, 2024	45	-16.67%	19,415,909	3.64%	65	1.04%	20	-35.48%	13	-18.75%
Mar 31, 2024	54	5.88%	18,733,564	-8.13%	79	1.26%	31	-3.13%	16	60.00%
Dec 31, 2023	51	37.84%	20,391,503	2.31%	79	0.76%	32	23.08%	10	25.00%
Sep 30, 2023	37	19.35%	19,931,490	69.75%	102	2.79%	26	136.36%	8	-50.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	749.42K	2.51%	-
Vanguard Institutional Extnd Mkt Idx Tr	261.93K	0.88%	-
Bridgeway Ultra-Small Company Market	161.30K	0.54%	59.51K
Fidelity Extended Market Index	118.48K	0.40%	-781.00
iShares Micro-Cap ETF	35.95K	0.12%	-
BlackRock Extended Equity Market K	33.77K	0.11%	-14.00
Extended Equity Market Fund K	33.31K	0.11%	-459.00
Bridgeway Ultra-Small Company	33.20K	0.11%	33.20K
Fidelity Total Market Index	31.26K	0.10%	-
Fidelity Series Total Market Index	28.46K	0.10%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jan 03, 2025	Day Lucy	Chief Financial Officer	Sell	$3.97K
Jan 03, 2025	Chanda Sanjay	Chief Development Officer	Sell	$3.97K
Jan 03, 2025	Prior Stephen David	Chief Strategy Officer	Sell	$2.72K
Jan 03, 2025	Eizen Joshua M	See Remarks	Sell	$12.96K
Dec 10, 2024	Readnour Robin Shane	-	Buy	$7.46K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	18	-
2024 Q3	1	2
2024 Q2	-	-
2024 Q1	-	12
2023 Q4	-	8

ANTX Ownership FAQ

Who Owns AN2 Therapeutics?

AN2 Therapeutics shareholders are primarily institutional investors at 45.28%, followed by 21.64% insiders and 33.08% retail investors. The average institutional ownership in AN2 Therapeutics's industry, Biotech Stocks , is 109.70%, which AN2 Therapeutics falls below.

Who owns the most shares of AN2 Therapeutics?

AN2 Therapeutics’s largest shareholders are Ra capital management (5.55M shares, 18.65%), Tcg crossover management (1.56M shares, 5.22%), and Citadel advisors (1.55M shares, 5.22%). Together, they hold 29.10% of AN2 Therapeutics’s total shares outstanding.

Does Blackrock own AN2 Therapeutics?

Yes, BlackRock owns 1.01% of AN2 Therapeutics, totaling 299.7K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 644.36K$. In the last quarter, BlackRock increased its holdings by 8.62K shares, a 2.96% change.

Who is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested?

Tcg crossover management is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.35% of its assets in 1.56M AN2 Therapeutics shares, valued at 3.34M$.

Who is the top mutual fund holder of AN2 Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of AN2 Therapeutics shares, with 2.51% of its total shares outstanding invested in 749.42K AN2 Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools